SIREN L L C
Q4 2025 Form 13-F

GREENWICH, DELAWARE
CIK 0002005245 · Institutional investment manager
Consolidated report · includes 2 managers since Q3 2024
$3.4B Reported Value Total
Reported value
$3.4B
Quarter over quarter
+25.1%
Holdings
113
Top-10 concentration
46.3%

Filing Structure

Reports holdings for

  • Invus Financial Advisors LLC · File #028-19938 · since Q3 2024
  • Invus Group, LLC (not a 13F filer in our records) · File #028-24462 · since Q3 2024

Key People

Named on the latest Form 13-F filing — not necessarily an owner
Raymond Debbane
President

Filing Navigation

13F Metrics

Loading 13F Metrics

Q4 2025 13F record

Q4 2025 13F filing summary

Q4 2025 Form 13F portfolio summary
Period of report December 31, 2025
Filed February 13, 2026
Form 13F-HR
Reported value $3.4B
Positions 113
Change in reported value +31.1%
New positions 26
Exited positions 28
Position turnover 38.3%
Top-10 concentration 46.3%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 12, 2026
110 $4.2B
Q2 2026 13F
Filed Aug 13, 2026
115 $4.9B
Q1 2026 13F
Filed May 14, 2026
100 $3.6B
Q4 2025 13F
Filed Feb 13, 2026
113 $3.4B
Q3 2025 13F
Filed Nov 13, 2025
115 $2.6B
Q2 2025 13F
Filed Aug 13, 2025
110 $1.9B
Q1 2025 13F
Filed May 14, 2025
116 $1.8B
Q4 2024 13F
Filed Feb 14, 2025
117 $2.3B
Q3 2024 13F
Filed Nov 13, 2024
109 $2.0B

Top 20 holdings · Q4 2025

Largest Q4 2025 13F positions by reported value
# Holding Reported value % of portfolio
1 SRRK Scholar Rock Holding Corp $476.8M 14.22%
2 KYMR Kymera Therapeutics Inc $255.7M 7.63%
3 ONC BeOne Medicines AG $151.9M 4.53%
4 EWTX Edgewise Therapeutics Inc $112.4M 3.35%
5 RVMD Revolution Medicines Inc $106.3M 3.17%
6 CNTA Centessa Pharmaceuticals PLC $100.7M 3.0%
7 ARWR Arrowhead Pharmaceuticals Inc $99.6M 2.97%
8 BCAX Bicara Therapeutics Inc $87.8M 2.62%
9 OLMA Olema Pharmaceuticals Inc $82.5M 2.46%
10 IRON Disc Medicine Inc $78.5M 2.34%
11 GPCR Structure Therapeutics Inc $75.0M 2.24%
12 TNGX Tango Therapeutics Inc $72.3M 2.16%
13 RCUS Arcus Biosciences Inc $71.7M 2.14%
14 STOK Stoke Therapeutics Inc $71.3M 2.13%
15 CRNX Crinetics Pharmaceuticals Inc $70.2M 2.09%
16 DYN Dyne Therapeutics Inc $68.5M 2.04%
17 APLS Apellis Pharmaceuticals Inc $64.8M 1.93%
18 COGT Cogent Biosciences Inc $57.9M 1.73%
19 SEPN Septerna Inc $55.8M 1.66%
20 TSHA Taysha Gene Therapies Inc $55.7M 1.66%

Values as reported on the Q4 2025 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings